Novartis (NVS) - Golden Cross Event!Novartis (NVS) reported earnings last week. A Golden Cross event (considered Bullish) occurred in the stock. The chart includes a technical and fundamental analysis of Novartis.
NVSEF trade ideas
Novartis Looking to long if all other position not filledWe will long this if all our other entries are not met
HistoryNVS is a long term play. Been holding this trendline (Outside of global pandemic market crash) for 4 years now. Slow and steady wins this race.
Still need a full correction NVS bounced nicely at my A point .382 FIB.
Unless we get dramatic news out of this one i still see us heading lower after a visit up around 86.
We should see a full 50% or even 61.8% retrace before heading back towards 90+
NVS retracingI can see this scenario playing out. A full ABC correction bringing us to a .5 retrace then a nice push up back toward 90. This one seems to be running up on news along in the short term. I am still holding my Fall expiring call options at a $100 strike. in the red right now, but no reason to dump yet.
Holding for now, and might even rebuy once i see the correction waves complete an we start heading back up.
My analysis for NOVARTIS In the NOVARTIS story , we have to scenarios :
• If the market breaks the 81,50 we can go back to 79,09 ;
• if it returns to the 84,94 then it will go up until 89,32.
Needs to Snap out of itNVS needs to react to this 83.15 fib level.
Mfl and RSI both oversold. MACD looking like it could be flattening out..
Needs to show me something before i add to my call positions..
Solid Earnings CallBullish on NVS right now. Earning call beats expectations, and maintains outlook. 91.27 next resistance.
NVS Gaps UPGapped up over the weekend. We tend to have flat days after gap ups overnight. Likely to do the same today. Earnings tomorrow, so that might change things..
Still in Call options right now up a few bucks as of Friday nothing crazy. Confident this thing will break $100 before the end of summer.
Happy with the finish to the weekVery Happy with NVS at the end of trading today getting back above 89. The bounce off of the .618 Fib line looks solid. Earnings come out next week, and in case anyone thought NVS only did COVID19 bullshit.. they do other stuff too. Look at their recent RMAT designation of their drug Kymriah
There are other things happening in the world other than COVID..
Holding Call options for Fall.
Earnings INCOMINGI like this stock.. Front lines of Covid testing so has good name recognition right now which generally causes retail investors to buy driving pricing up. Earnings report comes out in a few days which i am thinking should be higher than anticipated. (beat every quarterly estimate in 2019)
Long long long..
Call options boughtThis things been a monster for years... Earnings coming out next week should be solid.. Testing currently for COVID solutions.
Trading the News on this one.. No real charting on this one.. Grabbed some of this after reading the news about them running the FDA approved study for COVID 19 solutions..
www.bloomberg.com
Also earning come out in about a week which should be up from hydroxychloroquine sales..
Grabbed some June and July Call options here.. Looking for it to carry up towards $95+
Novartis: Buy opportunity with split entry.NVS was among the high cap losers yesterday on the renewed coronavirus tensions and pulled back dramatically (-6.90%). This however can be the buy opportunity of the next several months as it hit the 1D MA200 (orange line) and is approaching the Higher Low trend line of the 1W Channel Up (RSI = 45.378, MACD = 1.640, ADX = 65.865).
Even though the MACD indicated the possibility of a deeper pull to the 84.00 1W Support before a meaningful rebound, we give equal probabilities for the rebound to start within the Higher Low zone. Our Target zone is 98.00 - 100.00.
** If you like our free content follow our profile (www.tradingview.com) to get more daily ideas. **
Comments and likes are greatly appreciated.
Swing NVSName Novartis A G
Symbol NVS
Price to Activate $99.85
Stop Loss $92.85
1st Target $107.83
2nd Target $119.82
The Market continues to climb. Maybe stocks do grow to the moon. Our stock pick for tomorrow is NVS. Have a great evening and happy trading!
- Bernard
Novartis Long into earnings
Bullish setup into earnings.
Resistance @$96 could break post earnings.
RSI in long term uptrend, room to run higher.
Strong Moving average support.
NVS Long• NVS
• Why enter? Pullback continuation
• Entry: 94.38
• Stop loss: 93.98 (-.04%)
• Profit target 1: 96.14 (1.8%)
• Profit target 2: 98.00 (3.8%)
NOVARTIS - Trend Trade Idea SIX:NOVN
- Price has retraced to the major trendline & 200ma
- A break of the daily downtrend would confirm a good entry to get on the trend
- MANAGE YOUR RISK -
Disclaimer: All ideas are my opinion and should not be taken as financial advice.
Look to Long Novartis above $97 on breakout. NYSE:NVS earnings and sales also beat estimates and the company raised its guidance for the year. Its Pharmaceuticals business unit grew 10% driven by performance of key drugs like Cosentyx, Entresto and Lutathera while the Sandoz division rose 1% as strong uptake of biosimilars was offset by price erosion in the United States.
AVERAGE ANALYSTS PRICE TARGET $83
AVERAGE ANALYSTS RECOMMENDATION overweight
P/E RATIO 17
COMPANY PROFILE
Novartis AG is a holding company, which engages in the development, manufacture, and marketing of healthcare products. It operates through the following four segments: Innovative Medicines, Alcon, Sandoz, and Corporate. The Innovative Medicines segment researches, develops, manufactures, distributes and sells patented pharmaceuticals, and is composed of two business units: Novartis Oncology and Novartis Pharmaceuticals. The Alcon segment researches, develops, manufactures, distributes and sells eye care devices and vision care. The Sandoz segment develops, manufactures and markets finished dosage form medicines as well as intermediary products including active pharmaceutical ingredients. The Corporate segment refers to group management and central services. The company was founded on February 29, 1996 and is headquartered in Basel, Switzerland.
